Senthil Murugesan
A5036971865- Inflammatory Bowel Disease
- Biosimilars and Bioanalytical Methods
- Genetic factors in colorectal cancer
- Microscopic Colitis
- Cancer Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Stress Responses and Cortisol
- bioluminescence and chemiluminescence research
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Pharmaceutical studies and practices
- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Mycobacterium research and diagnosis
- Colorectal Cancer Screening and Detection
- Eosinophilic Esophagitis
- Neuroendocrine regulation and behavior
- Liver Diseases and Immunity
- Medical Imaging and Pathology Studies
- Tryptophan and brain disorders
Blackpool Teaching Hospitals NHS Foundation Trust
2017-2023
University of Liverpool
2015-2022
Blackpool Victoria Hospital
2015-2022
Syngene International (India)
2014
Biocon (India)
2014
Bristol-Myers Squibb (India)
2014
Background & AimsAnti–tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce formation of anti-drug antibodies. The ability to identify patients at increased risk development antibodies would facilitate selection therapy and use preventative strategies.MethodsWe performed a genome-wide association study variants associated with time in discovery cohort 1240 biologic-naïve Crohn's disease...
BackgroundWe sought to report the effectiveness of infliximab and adalimumab over first 3 years treatment define factors that predict anti-TNF failure strategies prevent or mitigate loss response.MethodsPersonalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting rates anti-TNF-naive patients with active luminal aged 6 older. At end year, sites were invited enrol participants still receiving drug into 2-year...
Summary Background Anti‐drug antibodies are associated with treatment failure to anti‐TNF agents in patients inflammatory bowel disease (IBD). Aim To assess whether immunogenicity a patient's first agent would be the second, irrespective of drug sequence Methods We conducted UK‐wide, multicentre, retrospective cohort study report rates and second therapies 1058 IBD who underwent therapeutic monitoring for both infliximab adalimumab. The primary outcome was agent, defined at any timepoint as...
Abstract Background and Aims Anti-tumour necrosis factor [anti-TNF] therapy is widely used for the treatment of inflammatory bowel disease, yet many patients are primary non-responders, failing to respond induction therapy. We aimed identify blood gene expression differences between responders non-responders anti-TNF monoclonal antibodies [infliximab adalimumab], predict response status from clinical data. Methods The Personalised Anti-TNF Therapy in Crohn’s Disease [PANTS] study a UK-wide...
A 68-year-old previously healthy man presented with increasing right hip pain of 6 months duration. On examination he was found to have a hard mass in the arising from pelvic bone. Imaging studies were keeping sarcoma iliac However, biopsy this bony lesion confirmed be metastatic adenocarcinoma rather than primary bone malignancy. Further imaging and subsequent colonoscopy revealed colonic adenocarcinoma. The unique unusual nature case presentation as solitary metastasis primary. There is no...
Colorectal Carcinoma is the second biggest killer after lung and bronchial carcinoma. Due to its insidious onset late manifestation of symptoms a national screening programme was started in 2006 within UK. We present rare case colorectal adenocarcinoma mimicking osteosarcoma presenting as hip pain at initial consultation orthopaedic clinic. Further adding rarity this that an apparent bony metastasis isolation. Our demonstrates vital role histological sampling plays diagnosis treatment...
Background: Data on reason for change of biologic therapy mostly comes from clinical trials and hospital case series. This interim analysis presents data reasons among participants in the vedolizumab Post Authorisation Safety Study (PASS). Methods: The PASS study is a multicentre prospective observational cohort adult IBD patients starting or switching to new agent 23 countries North America Europe. focused recruited up 30 September 2016, who at recruitment were experienced initiating...
Abstract Background Chronic ulcerative colitis is an inflammatory condition associated with a pro-neoplastic drive, predisposing to colorectal cancer. Repeated colonoscopy undertaken detect preneoplastic change, but cancer diagnosis still frequently missed. Aims To determine if predetermined panel of methylation markers could better risk stratify patients, aiding earlier detection neoplasia. Methods ENDCaP-C ( https://doi.org/10.1186/ISRCTN81826545 ) was prospective multicentre test accuracy...
Background Chronic ulcerative colitis is a large bowel inflammatory condition associated with increased colorectal cancer risk over time, resulting in 1000 colectomies per year the UK. Despite intensive colonoscopic surveillance, 50% of cases progress to invasive before detection. Detecting early (precancer) molecular changes by analysing biopsies from routine colonoscopy should increase neoplasia Objectives To establish deoxyribonucleic acid (DNA) marker panel neoplastic patients. develop...